ESMO Congress

Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib

October 03, 2019

Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.

Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer

October 02, 2019

George Sledge, Jr., MD, discusses the overall survival data of the phase III MONARCH-2 trial in advanced hormone receptor-positive, HER2-negative breast cancer.

Nivolumab Plus Ipilimumab Shows Durable Clinical Activity in Cervical Cancer

October 01, 2019

In the CheckMate-358 study, the combination of nivolumab and ipilimumab showed durable clinical activity in patients with recurrent or metastatic cervical cancer, regardless of tumor PD-L1 expression.

Nivolumab Improves OS in Advanced Esophageal Cancer

October 01, 2019

In the phase III ATTRACTION-3 study, nivolumab prolonged overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma, according to findings presented at the 2019 ESMO Congress.

Pembrolizumab Does Not Improve PFS Over Chemotherapy in Relapsed Malignant Pleural Mesothelioma

September 30, 2019

Progression-free survival was not improved with pembrolizumab over chemotherapy in patients with malignant pleural mesothelioma, missing the primary endpoint of the phase III European Thoracic Oncology Platform PROMISE-meso trial presented at the 2019 ESMO Congress.

Risk of Progression or Death Reduced With Ivosidenib in Advanced Cholangiocarcinoma

September 30, 2019

The risk of progression or death was reduced by 63% with ivosidenib as treatment of pretreated patients with IDH1-mutant advanced cholangiocarcinoma compared with placebo, according to data from the phase III ClarIDHy study that was presented at the 2019 ESMO Congress.

Abemaciclib Leads to Positive Benefit in Chinese Women With HR+ Breast Cancer

September 30, 2019

CDK4/6 inhibitor abemaciclib plus endocrine therapy led to significant benefits in a population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer, according to data from 2 randomized trials presented at the 2019 ESMO Congress.

First-Line Atezolizumab/Chemotherapy Improves Outcomes in Metastatic Urothelial Cancer

September 30, 2019

In patients with locally advanced or metastatic urothelial carcinoma, atezolizumab and chemotherapy improved median progression-free survival by 1.9 months compared with placebo and chemotherapy. However, no overall survival benefit was seen, according to results of the phase III IMvigor130 trial presented at the 2019 ESMO Congress.

Olaparib Improves rPFS in Heavily Pretreated HRR+ mCRPC

September 30, 2019

In the phase III PROfound trial, olaparib improved radiographic progression-free survival compared to either abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer, who had homologous recombination repair gene alterations, according to findings presented at the 2019 ESMO Congress.

Use of Sacituzumab Govitecan in Metastatic Urothelial Carcinoma

September 30, 2019

Scott T. Tagawa, MD, discusses data from the phase II TROPHY-U-O1 trial in patients with metastatic urothelial cancer, presented at the ESMO Congress 2019.